Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of “Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $11.36.

A number of research firms have recently weighed in on VOR. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research report on Monday, December 9th. JMP Securities reiterated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Finally, Robert W. Baird reduced their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Vor Biopharma Trading Down 3.6 %

NYSE VOR opened at $1.33 on Wednesday. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43. The company has a 50 day moving average of $1.23 and a 200-day moving average of $0.97. The company has a market cap of $91.33 million, a price-to-earnings ratio of -0.81 and a beta of -0.45.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Exchange Traded Concepts LLC boosted its position in Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after buying an additional 48,017 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma in the second quarter valued at approximately $53,000. Virtu Financial LLC bought a new stake in Vor Biopharma during the 4th quarter worth $60,000. Rosalind Advisors Inc. bought a new stake in Vor Biopharma during the 3rd quarter worth $54,000. Finally, Renaissance Technologies LLC grew its position in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after acquiring an additional 160,642 shares during the last quarter. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.